title: Efficacy of surface ablation retreatments using mitomycin C.
abstract: OBJECTIVE
  To evaluate the visual and refractive results and the incidence of complications after laser subepithelial keratectomy (LASEK) enhancement using mitomycin C (MMC) after a previous LASEK procedure with MMC.
  
  
  METHODS
  Retrospective, noncomparative, interventional case series.
  
  
  METHODS
  Setting was Vissum Santa Hortensia, Madrid, Spain. We performed a retrospective study of LASEK-treated eyes that received intraoperative MMC for 30 seconds and that needed an enhancement procedure. LASEK retreatment with MMC 0.02%, applied for 60 seconds, was performed 3 to 6 months after the initial surgery. We measured the visual and refractive results 3 months after the enhancement and the incidence of complications.
  
  
  RESULTS
  Eighty-two eyes were included in the study. The preoperative data were best spectacle-corrected visual acuity (BSCVA) 1.08 +/- 0.19, sphere -4.68 +/- 2.8 diopters (D), and cylinder -1.30 +/- 1.20 D. Three to 6 months postoperatively, before enhancement, the uncorrected VA (UCVA) was 0.59 +/- 0.2; the BSCVA, 0.976 +/- 0.2; the residual sphere, +0.17 +/- 0.7 D, and the cylinder, -0.39 +/- 0.5 D. Three months after retreatment, the UCVA was 0.93 +/- 0.1; the BSCVA, 0.977 +/- 0.1; the residual sphere, 0.09 +/- 0.3 D; and the residual cylinder, -0.2 +/- 0.3 D. The safety index after retreatment was 1.01 +/- 0.1, and the efficacy index was 0.96 +/- 0.1. No haze, no delay in epithelial healing, and no case of endothelial decompensation were detected.
  
  
  CONCLUSIONS
  Surface ablation retreatment using MMC seems to be effective to correct residual refractive errors after an initial surgery with MMC.
authors.affiliation: Vissum Madrid, Santa Hortensia 58, Madrid, Spain. lbenito@vissum.com
authors.forename: Laura
authors.initials: L
authors.lastname: de Benito-Llopis
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Teus
mesh_terms: D000328:Adult; D000477:Alkylating Agents / Q000008:administration & dosage*; D001251:Astigmatism / Q000503:physiopathology / Q000601:surgery*; D003131:Combined Modality Therapy; D003315:Cornea / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D007431:Intraoperative Complications; D049008:Keratectomy, Subepithelial, Laser-Assisted / Q000379:methods*; D054018:Lasers, Excimer / Q000627:therapeutic use*; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage*; D009216:Myopia / Q000503:physiopathology / Q000601:surgery*; D011183:Postoperative Complications; D012029:Refraction, Ocular / Q000502:physiology; D012086:Reoperation; D012189:Retrospective Studies; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology; D055815:Young Adult
chemical_list: D000477:Alkylating Agents; D016685:Mitomycin